Introduction
Gaucher disease is the most common glycolipid storage disorder, with an incidence of approximately 1:60 000 in the general population and 1:800 in the Ashkenazi Jewish population. 1, 2 It results from a deficiency in the activity of ␤-glucocerebrosidase, which cleaves the ␤-glucosidic linkage of glucosylceramide to produce ceramide and glucose. This breakdown normally occurs in the lysosomal compartment of the cell. In the absence of ␤-glucocerebrosidase activity the uncleaved lipid substrate is stored in lysosomes within cells of the macrophage lineage, mostly affecting the spleen, liver, bones and bone marrow. The central nervous system (CNS) may also be involved and depending on the degree of its involvement, Gaucher disease can be divided into three types. 3, 4 Type 1 is nonneuronopathic and the most prevalent form of disease seen in adults. Type 2 is an acute neuronopathic form resulting in death in infancy, while type 3 is a subacute neuronopathic form with a variably delayed neuronopathic course that usually results in death between the second and fourth decade of life. Different point mutations, insertional mutations, deletions and splicing mutations in the ␤-glucocerebrosidase gene have been described, which lead to the heterogeneity of clini-cal lesions. 5 There is a relationship between the type of mutation and the clinical manifestation of the disease 6, 7 but there is also some degree of variability among patients with the same disease genotype. 5 Current treatment for most Gaucher patients is still supportive and symptomatical, dealing with clinical manifestations (hepatosplenomegaly, anaemia, osseous lesions, fibrosis, cirrhosis etc) rather than with the cause of the disease. Other available options are enzyme replacement therapy, 8, 9 allogenic bone marrow transplantation 10, 11 and, potentially, somatic gene therapy by gene transfer into haematopoietic stem cells (HSCs). [12] [13] [14] It seems that regardless of the approach used, therapy has to start well before neurological symptoms and severe neuronal damage develop and the most promising candidates are type 1 and possibly type 3 Gaucher patients.
Enzyme replacement is based on administration of the missing enzyme in a form that is enriched with terminal mannose moieties to target the enzyme to the high affinity mannose-6-phosphate receptors on macrophages. Although therapeutically effective to some extent (regression of organomegaly, increase in the haemoglobin concentration), 8, 9 enzyme replacement is expensive, gives only limited improvement in neuronopathic disease due to the inaccessibility of the CNS 15, 16 and the enzyme is not targeted to marrow macrophages. 2 Little activity was found in bone marrow cells, even immediately after marrow infusion. 2, 17 The enzyme is also bound by cells other than macrophages via the widely distributed, low affinity mannose receptor. Figure 1 ( Bone marrow transplantation (BMT) has been performed only in patients with severe disease. It requires a human lymphocyte antigen (HLA) identically matched donor and ablation of the patient's own marrow before transplantation. The mortality risk for the procedure is around 10% because of the patient's severely compromised condition. Marrow ablation produces a period of pancytopenia and immunocompromise and there is also the possibility of graft-versus-host disease. Genetic modification of the patient's own HSCs by introducing a correctly expressed copy of the gene, followed by autologous bone marrow transplantation would overcome problem of graft-versus-host disease and shortage of donors.
Here, we describe a construct suitable for gene therapy which utilises the murine MHC class II Ea d locus control region (LCR) 18 and drives expression of the transgene, in this case human ␤-glucocerebrosidase, to the cells that constitutively express class II molecules such as B cells, monocytes, macrophages, dendritic cells, myeloid and erythroid precursors and some epithelial cells. Use of the full genomic sequence of the gene in conjunction with the MHC class II LCR, rather than the more commonly used cDNA, increases the likelihood of the enzyme being expressed at the significant levels that would be required for effective gene therapy.
Results
Human ␤-glucocerebrosidase was expressed in transgenic mice using a construct consisting of a murine MHC class II LCR linked to the human ␤-glucocerebrosidase gene. Approximately 25 kb of the Balb/c MHC class II IEa d locus was used, comprising all of the 5′DNaseI hypersensitive sites, the promoter and transcriptional start site. The human ␤-glucocerebrosidase gene was supplied as a genomic fragment starting in the first exon before the translational start site and including all introns and polyadenylation signals.
Five founder mice carrying the construct MHCclassII/␤glu were obtained ( Figure 1a ) and checked for the integrity of the 35 kb transgene (Figure 1b ). All five founders contained the intact locus. Four of the founder mice transmitted the transgene to the F1 generation. The copy numbers of these lines were determined ( Figure 1c ) and found to be: lines 5 and 15 -15 copies, line 6 -seven copies and line 11 -two copies. Expression studies were done using F1 heterozygous mice. The level of expression of the enzyme was determined for all four lines by measuring the activity in the spleen of 2-month-old mice (Figure 2) . A high level of expression was expected due to the substantial proportion of MHC class II-positive B cells in this organ. To discriminate between endogenous (mouse) and transgenic (human) enzyme activity, the human enzyme was specifically immunoprecipitated from total spleen extracts using the monoclonal antibody 8E4. 19, 20 Immunoprecipitated ␤-glucocerebrosidase activity was detected using the artificial substrate 4-methylumbelliferyl-␤-glu (4-MU␤glu). On enzymatic breakdown of this substrate, 4-MU is released and its fluorescence can be measured.
No human activity was detected in the control nontransgenic mice or in the mouse macrophage-like cell line, RAW264. Activity was detected in all four transgenic lines and in the human cell line U937. Enzyme activities for different mice from the same line were of a similar level.
In all cases the level of human ␤-glucocerebrosidase activity correlated with the number of copies of the transgene. Thus, line 11 (two copies) had the lowest activity, line 6 (seven copies) an intermediate level, and lines 5 and 15 (15 copies each) an equal, high level of expression. The low activity of line 11 compared with that of U937, an immortalised human cell line is explained by the fact that this is the activity in the total spleen (ie a mixture of cells) rather than a homogeneously expressing population as is the case for U937.
FISH analysis using the whole injection fragment on bone marrow cells showed the integration sites of the transgenes to be either telomeric (lines 5 and 6) or centromeric (lines 11 and 15) ( Figure 3 ). In centromeric regions it is likely that the transgenes will be integrated in transcriptionally silent heterochromatin. From this fact and the copy number-dependent expression of the linked gene, it seems that the MHC class II I-Ea d fragment is able to function fully as an LCR when attached to the heterologous ␤-glucocerebrosidase gene. This makes it particularly interesting for use in gene therapy protocols where the integration site of the transgene into the host genome still cannot be controlled. Without the use of an LCR-like element integration of the gene into heterochromatin, which makes up a large part of the genome, would result in position effects and low levels of expression. 21, 22 Immunofluorescent staining of spleen single cell suspensions with the rabbit polyclonal antibody R386 against human ␤-glucocerebrosidase showed that approximately 60% of the cells from transgenic spleens were positive for the human enzyme ( Figure 4d ) which is the same as the percentage of B cells present in the organ. From double staining with B and T cell markers (data not shown), expressing cells are indeed B220 positive and therefore B but not T cells are responsible for the activity in the spleen. The fact that all B cells were positive shows that integration into the centromeric region did not lead to position effect variegation (PEV). 21, 22 In vitro cultured macrophages from transgenic and nontransgenic mice were stained in situ with the polyclonal antibody R386 and with the mature mouse macrophage markers F4/80 and MOMA-2. The F4/80 antigen is found on the membranes of macrophages in most tissues of the body, whereas MOMA-2 is primarily cytoplasmic and is found mainly on macrophages in a lymphatic environment. 23 Cells were taken from spleen, bone marrow and the peritoneal cavity (after induction of a sterile inflammatory response) and cultured in the presence of L cell-conditioned medium on untreated glass coverslips. After 7 days of culture, most if not all, adherent cells expressed The cultured cells adopted a macrophage-like morphology, extending long plasma membrane processes and making contact with other cells. Splenic macrophages could be seen to have engulfed smaller cells, probably dead lymphocytes also present in the culture.
Staining of the cultured macrophages for human ␤-glucocerebrosidase revealed that most but not all F4/80-positive cells from transgenic animals contained the human enzyme, whereas no staining was seen in control cultures.
In order to determine whether other cells belonging to mononuclear phagocyte system (eg Kupffer cells in the liver) express the transgene, RT-PCR was performed, using primers specific for human ␤-glucocerebrosidase, on different tissues (spleen, liver, kidney, bone marrow, thymus, brain, lungs, testis and ovary). The 581 bp fragment corresponding to the human mRNA could be distinguished from amplification of contaminating DNA in the samples due to the use of primers spanning an intron. The correct fragment was observed in all tissues tested ( Figure 6 ) from all transgenic lines, and not in nontransgenic controls. RT-PCR on tissues from the lowest copy number line (line 11, two copies) showed that there was low expression in the brain. Considering that the number of microglial cells which are the resident macrophages of the CNS is high (15%), it could be expected that the brain would have a high level of expression if these cells were positive. Thus the PCR result suggests that the MHC class II LCR does not drive high levels of expression in microglial cells. Obviously, the PCR result does not distinguish between cell types and the expression in a number of tissues could be the result of the presence of circulating B cells.
Thus the localisation of the human enzyme was analysed by immunohistochemistry on cryosections of the same tissues which were used for RT-PCR, using the polyclonal antibody R386 alone or in combination with macrophage and dendritic cells markers (F4/80 and N418 24 ). Indeed, the resident macrophages were found to be positive for human ␤-glucocerebrosidase: Kupffer cells in the liver (Figure 7b ), alveolar macrophages in the lung (Figure 7c) , macrophages of the lamina propria throughout the gastrointestinal tract (Figure 7d ), kidney resident macrophages in the renal medullary and cortical interstitium and juxtaglomerular complex (Figure 7e ), spleen resident macrophages in both red and white pulp, as well as those in the marginal zone (Figure 7f ). In the thymus, not only macrophages and dendritic cells but also thymic epithelial cells were strongly stained (Figure 7g ). R386 + cells in brain sections appeared to be perivascular macrophages, based on their morphology and obvious association with the vasculature, and not the extensively arborised parenchymal microglial cells (Figure 7h) .
To estimate the activity of the human enzyme in the brain of transgenic animals in comparison with that in the spleen and liver, human-specific immunoprecipitation was again performed using the monoclonal antibody 8E4. Considerably older animals (approximately 2 years) of lines 5 (15 copies) and line 6 (seven copies) were used. As expected from the immunohistochemical data the level of enzyme activity in the brain was extremely low in comparison with levels in the liver and spleen (Figure 8 ).
Discussion
For effective treatment of Gaucher disease it is necessary to achieve sustained expression of the glucocerebrosidase gene in macrophages, as these are the important cells for the pathogenesis of the disease. Therefore, we have used a murine MHC class II LCR to drive the expression of human ␤-glucocerebrosidase in the cell type of interest, rather then using other LCRs to overproduce and to secrete the missing enzyme from other cell types. The ␤ globin LCR, for example, was used to overexpress protective protein/cathepsin A in erythroid precursor cells to treat another lysosomal disorder, namely galactosialidosis. 25 In transgenic mice LCRs confer high level expression on linked genes independent of the position of the transgene in the mouse genome. It is known that an incomplete LCR loses this property when integrated into a heterochromatic region. 21, 22 As two of the four transgenic lines that we have generated had the transgene in the centromeric region, and both were expressing human enzyme according to their copy number, we conclude that the fragment of murine MHC class II Ea d LCR used, with its 5 DNase hypersensitive sites, 18 can fully act as an LCR when linked to genomic sequences of a heterologous gene. The same fragment was previously used linked to the cDNA encoding Bruton tyrosine kinase (BTK). 26 Only two of five transgenic mice lines expressed BTK and rescued the BTK−/− phenotype, most likely due to the use of the cDNA rather than anything missing from the LCR element. Recently, the same LCR fragment has been used linked to a part of the same cDNA followed by large piece of genomic BTK sequence. All transgenic lines obtained expressed. 27 Therefore, we would like to stress the importance of the presence of intervening sequences for any future gene therapy protocols. It seems that the last intervening sequence of multiple intron containing genes is a principal determinant of the efficiency of 3′ end formation and perhaps post-transcriptional regulatory steps in gene expression. 28 It is well known that class II antigens are expressed on a limited subset of cells in the immune system, including B cells, macrophages, dendritic cells, thymic epithelium and activated T cells in most species, but not the mouse. 29 The level of class II is not static in these cells but can be up-or down-regulated by a large number of external stimuli. However, there is a difference in basal level of MHC class II expression among the cells of the macrophage lineage. Macrophages differ from other haematopoetic cells in that they form a resident population in many tissues of the body. 30 They are generated in the bone marrow and circulate in the blood as monocytes before reaching their target tissues. Once they have entered the tissue, they are known as macrophages, or in some tissues by more specialised names such as Kupffer cells in the liver.
In all the organs of our transgenic mice, resident macrophages expressed human ␤-glucocerebrosidase (with the exception of the brain). The obvious question that arises is why the microglial cells do not express. The origin and biological functions of microglia are still unclear and debatable. Resident microglia appear in the CNS during late post-natal development. 31 These cells lack many of the surface features and functional properties typically associated with macrophages found in other tissues. 32, 33 The brain has been thought of as an immunologically privileged site. It lacks a lymphoid system and there is no evidence for a population of dendritic cells. The expression of class II antigens on cells in the CNS, which might then act as antigen-presenting cells, does not occur in the normal rodent 34 but is variable in studies of the human CNS. 35 The expression of class II antigens has been demonstrated on microglia in a variety of pathological conditions, such as brain injury, Parkinson's disease, Alzheimer's disease and demyelinisation. Recently, it has become possible to clone microglial precursors in agar and expand them in liquid culture. Some of the in vitro cultured microglial clones expressed class II MHC, but expression was not sufficient for the processing and presentation of complex protein antigens to T cells. 36 Other reports show that in vitro cultured microglia can be induced to express class II MHC antigens upon IFN␥ treatment and indicate the absence of expression on unstimulated microglia 37, 38 or the normal brain in vivo. under the control of MHC class II LCR, its expression follows the expression pattern of class II molecules. This would explain the lack of human ␤-glucocerebrosidase activity in parenchymal microglial cells of adult transgenic mice. However, using the retroviral vector G2, containing the human glucocerebrosidase cDNA driven by Maloney murine leukemia virus long terminal repeats (LTR), Krall et al 13 reported that retrovirally transduced murine BM cells can repopulate up to 20% of the total microglia, but the majority (approximately 90%) of cells appear to be perivascular microglia and only 5-10% parenchymal microglia. This shows that significant numbers of cells are capable of infiltrating the CNS after BMT, but it does not reveal how much microglial expression is required to achieve a therapeutic effect in neuronopathic types of disease.
For many genetic disorders such as sickle cell anaemia and ␣ and ␤ thalassaemias, it is important to correct the defect by providing a functional single copy of the diseased gene. Introduction and expression of more than one copy leads to pathology, for example, precipitation of overexpressed unpaired ␣ or ␤ globin chains, results in red cell lysis and anaemia. It seems that overexpression of human ␤-glucocerebrosidase (up to 15 copies in our experiment) did not cause any pathology in transgenic mice. There is no reason to suspect that the levels of enzymatic activity measured in vitro cannot be directly related to the amount of active enzyme in vivo. It is therefore reasonable to assume that overexpression will not cause any harmful effect in patients.
In type 1 Gaucher disease, accumulation of glucocerebroside is mainly restricted to bone marrow-derived macrophages outside of the CNS, and therefore type 1 disease would be a good candidate for somatic gene therapy using this construct. The observed beneficial response after allogenic BMT in patients with type 1 and type 3 Gaucher disease makes the transfer of the normal glucocerebrosidase gene under the control of appropriate LCR elements into HCSs followed by autologous BMT an attractive approach to consider.
Materials and methods

Construct
The gene for human ␤-glucocerebrosidase was isolated from plasmid PCN 9RI (a generous gift from E Ginns, Bethesda, MD, USA) as a 9.7 kb BamHI-EcoRV fragment using RecA-mediated single site cleavage 40 to cut uniquely at the BamHI site in exon 1 of the gene, before the ATG. The sequence of the oligo used to protect the BamHI site was as follows: 5′-CTCTGAAGGATAGAG-GATCCACTAAACAAAAACAAGGA-3 (BamHI site underlined). The fragment was subcloned into BamHIEcoRV of pBS II SK + (Stratagene, La Jolla, CA, USA) resulting in plasmid pBS␤glu. The mouse H2-I Ea d gene was deleted from cosmid 32.1 18 by the removal of a 10 kb PvuI-XhoI fragment. The remaining 25 kb fragment containing the 5 DNaseI hypersensitive sites of the mouse MHC class II Ea d LCR was blunted using Klenow and ligated to the blunted 9.7 kb NotI-ClaI human ␤-glucocerebrosidase fragment from pBS␤glu resulting in the cosmid MHCclassII/␤glu.
Generation of transgenic mice
A 35 kb NruI fragment from cosmid MHCclassII/␤glu was purified using a NaCl gradient. 41 The fragment was microinjected into fertilised mouse oocytes (FVB × FVB) at a concentration of 4 ng/l. Injected eggs were transferred into pseudopregnant mice and transgenic offspring identified by Southern blot analysis of tail DNA. 42 When using the whole cosmid as a probe, the labelled probe was prehybridised with sonicated genomic mouse DNA to prevent cross-hybridisation with repetitive sequences in the genome. For estimation of copy number, equal amounts of BamHI-digested, transgenic mouse and human genomic DNA were Southern blotted and the blot probed with a probe taken from exon 10 of the human ␤-glucocerebrosidase gene (almost identical to the mouse sequence). The probe was cloned as a 150 bp Asp718-BsrFI fragment into Asp718/XmaI of pBS II SK + and cut out as a 250 bp BssHII fragment. Quantification was carried out using a Phosphor Imager (Molecular Dynamics, Sunnyvale, CA USA), taking into account the relative genome sizes of mouse and human and the fact that the human and transgenic line 15 samples were homozygous.
In vitro culture of murine macrophages Two-month-old transgenic and nontransgenic mice were injected intraperitoneally with 0.5 ml of 3% Thiogycolate (Sigma, Zwijndrecht, The Netherlands) in phosphatebuffered saline (PBS). Mice were killed 4 days later. Peritoneal macrophages were collected by flushing the peritoneal cavity several times with PBS, using a Pasteur pipette. For bone marrow-derived macrophages, mouse femurs were cleaned, cut open and the bone marrow removed by injection of PBS through a needle. A single cell suspension was made by pipetting the cells up and down. For spleen-derived macrophages, a single cell suspension was made in PBS by passing the tissue through a 100 m mesh. All the samples were centrifuged for 5 min at 95 g and the cells plated on coverslips in 3 cm dishes in Iscove's modified Dulbecco's medium (Sigma) with 10% FCS and 10% L-cell conditioned medium as a source of M-CSF. L-cell medium was harvested when cells were almost confluent, the supernatant was centrifuged, filtered and added to macrophage cultures.
Immunocytochemistry
Different organs from nontransgenic and transgenic mice were embedded in Tissue-Tek (Sakura Finetek Europe, Zoeterwoude, The Netherlands) and frozen in liquid nitrogen. Cryostat sections, 7 m thick, were air dried and fixed in 3% paraformaldehyde (PFA) in 0.1 m sodium phosphate buffer pH 7.4 for 10 min. Cells were permeabilised and endogenous peroxidase activity blocked by incubation in 0.3% H 2 O 2 in methanol for 20 min. Subsequently, slides were washed in PBS + (PBS/0.5% BSA/0.02 m glycine). Slides were incubated at 4°C overnight with rabbit polyclonal anti-human ␤-glucocerebrosidase antibody R386 (1:500 dilution), washed in PBS + solution for 10 min and incubated for 30 min at room temperature with horseradish peroxidase (HRP)-conjugated swine anti-rabbit Ig (1:100) (DAKO, Glostrup, Denmark). Slides were washed in PBS + for 10 min and exposed for 5-10 min to Peroxidase Substrate (3,3′-Diaminobenzidine Tetrahydrochloride (DAB) tablets; Sigma). After washing in PBS slides were counterstained with hematoxylin, washed again and mounted in modified Aquamount mountant (BDH, Poole, UK).
For staining of cultured macrophages, coverslips with adherent cells attached were taken from culture dishes after 7 days of culture and washed once in PBS and once in PBS + . Cells were fixed in 3% PFA in 0.1 m Na phosphate buffer pH 7.4 for 10 min and directly transferred into 100% methanol at room temperature for 20 min. The coverslips were washed twice in PBS + before incubating with the antibodies for 45 min. R386 was used at 1:500 dilution. The rat monoclonal antibodies MOMA-2 and F4/80 (a kind gift from Peter Leenen, Erasmus University, Rotterdam) were used as undiluted cultured supernatants. The samples were washed three times in PBS + and incubated for 30 min with goat anti-rabbit IgG-FITC antibody (1:100) (Sigma) and/or donkey anti-rat IgG-cy3 (1:100). After washing in PBS, coverslips were mounted in Vectashield mount (Vector Laboratories, Burlingame, CA, USA) containing 0.75 g/ml DAPI and analysed under the fluorescence microscope (Leitz, Wetzlar, Germany).
␤-glucocerebrosidase enzymatic activity assay Enzyme activity was assayed in the spleen, liver and brain of transgenic and nontransgenic mice. Spleens were made into single cell suspensions and liver and brain were homogenised. The spleen cells were washed three times in phosphate-buffered saline (PBS) and the pellet dissolved in 200 l PBS. All samples were then sonicated for 3 s. Triton X-100 was added to a final concentration of 0.1%. Cell debris was removed by centrifugation for 10 min at 16 000 g at 4°C. Supernatants were transferred into new tubes and the protein concentration was measured using Coomassie Plus protein assay reagent (Pierce, Rockford, IL USA). Immunoprecipitation was performed using the monoclonal antibody 8E4 MoAb 19, 20 (diluted 1:2500. 100 g of protein extract and 30 l of Protein G Sepharose (Pharmacia Biotech, Uppsala, Sweden) were incubated with the antibody in PBS/0.5% BSA, in a total volume of 500 l at 4°C overnight on a rotating wheel. The beads were washed six times in PBS/BSA (10 s spin at 16 000 g). After the last wash the beads were carefully drained and resuspended in 40 l of assay medium containing 5 mm 4-methylumbelliferyl-␤-d-glucopyranoside (Sigma) in substrate buffer (0.2 m sodium phosphate-citric acid buffer pH 5.8, 0.15% Triton X-100, 0.3% synthetic sodium taurocholate (Sigma)). The beads were incubated at 37°C for 1 h. The reaction was terminated by adding 200 l of sodium carbonate buffer pH 10.7. Samples were centrifuged and 200 l of supernatant was used for measurement of 4-methylumbelliferone in a fluorimeter. As a standard 750 pmol 4-methylumbelliferone (Sigma) was used.
DNA FISH analysis
Extracted bone marrow was cultured for 24 h in RPMI medium (GIBCO BRL, Breda, The Netherlands). Chromosome preparations were made according to standard procedures. FISH was carried out as described by Mulder et al. 43 The entire 35 kb NruI injection fragment was used as a probe. The probe was labelled with dioxygenin and immunochemically detected with FITC. The DNA was counterstained with DAPI.
RT-PCR
For RT-PCR analysis, RNA was isolated from different tissues using the Ultraspec RNA isolation system (Biotecx Laboratories, Houston, TX, USA). cDNA was synthesised in a 50 l reaction using reverse transcriptase (Super RT; HT Biotechnology, Cambridge, UK) and an oligo(dT) primer. PCR reactions were performed in 50 l PCR buffer (Life Technologies, Paisley, UK) with 1.5 mm MgCl 2 , 100 ng of each primer, 1 l RT reaction, 0.2 mm each dNTPs and 2.5 U Taq DNA polymerase (Pharmacia). Thirty cycles of amplification were performed with denaturation at 94°C for 45 s, annealing at 60°C for 30 s and extension at 72°C for 45 s. PCR products were visualised by electrophoresis on a 2% agarose gel. Primers specific for the human ␤-glucocerebrosidase transgene were used -forward primer: 5′-GCCTTTGAGTAGGGTA AGCA-3′ and reverse primer: 5′-AGGAGTGAAA CGGGACGCCT-3′. Primers specific for murine hypoxanthine phosphoribosyltransferase (HPRT) were 5′-CACAGGACTAGAACACCTGC-3′ and 5′-GCTGGTGA AAAGGACCTCT-3′.
